2,3-diphosphoglycerate: a physiological inhibitor of platelet aggregation.
2,3-Diphosphoglycerate (2,3-DPG) may inhibit the platelet release reaction and the irreversible aggregation of human blood platelets induced by adenosine diphosphate, epinephrine, or norepinephrine. The effects of 2,3-DPG on platelet aggregation were more pronounced in cases with low hematocrit (less than 30 percent). Dipyridamole and vincaminor potentiated the antiaggregating effect of 2,3-DPG. Erythocytes (10-3 to 10-4 per microliter) exhibited a similar antiaggregating effect, especially when secured from anemic patients.
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors; D001777:Blood Coagulation / Q000187:drug effects; D003864:Depression, Chemical; D004163:Diphosphoglyceric Acids / Q000494:pharmacology*; D004176:Dipyridamole / Q000494:pharmacology; D004357:Drug Synergism; D004837:Epinephrine / Q000037:antagonists & inhibitors; D006400:Hematocrit; D006801:Humans; D066298:In Vitro Techniques; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010973:Platelet Adhesiveness / Q000187:drug effects*; D010974:Platelet Aggregation / Q000187:drug effects*; D014748:Vinca Alkaloids / Q000494:pharmacology
D004163:Diphosphoglyceric Acids; D014748:Vinca Alkaloids; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D009638:Norepinephrine; D004837:Epinephrine